Stocks
C4 Therapeutics, Inc.CCCC
NASDAQHealthcareBiotechnology$3.06
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted protein degradation therapies, primarily for cancer. Its lead programs focus on degraders for oncogenic targets such as BRAF and Cdc7, with early-stage clinical trials underway. Investors track C4 Therapeutics for its potential in the emerging field of molecular glue and PROTAC-based drug discovery.
52W Range: $1.69-$5.17
Congressional Interest in C4 Therapeutics, Inc. (CCCC)
No congressional trades have been disclosed for C4 Therapeutics, Inc. (CCCC) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CCCC?
No congressional trades found for this stock.